Description

The carbapenem drug market in China in terms of revenue is set to grow by US$ 493 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.6% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for carbapenem drug. The China carbapenem drug market is segmented on the basis of application. By application, it is categorized into city public hospital, and others.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Merck KGaA, Shenzhen Haibin Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the carbapenem drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Application: city public hospital, and others
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China carbapenem drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the carbapenem drug market in China looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Carbapenem Drug Market by Application
4.1 City Public Hospital
4.2 Others
5. Company Profiles
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Merck KGaA
5.3 Shenzhen Haibin Pharmaceutical Co., Ltd.
5.4 Sumitomo Dainippon Pharma Co., Ltd.
6. Appendix
6.1 About StrategyHelix
6.2 Disclaimer